BPByron K. Peters

Byron K. Peters

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Byron K. Peters has a total of 222 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Development of a Continuous Trickle-Flow Hydrogenation Process for Cbz Deprotection in Dipeptide Synthesis

    by Michael Whittington, Longrui Chen, Jacob H. Waldman, Michael J. Di Maso, Byron K. Peters, Mark Weisel, Gerard Klinzing, Tuyen Cao, FrançoIs LévEsque

    The synthesis of enlicitide decanoate (MK-0616), a first-in-class oral PCSK9 inhibitor, requires efficient Cbz deprotection of a proline–threonine dipeptide intermediate, presenting safety and economic challenges for traditional batch hydrogenation. Here, we report the development of a continuous trickle-bed flow reactor with customized components that addresses these manufacturing constraints through systematic process optimization. This paper reports the development of a laboratory-scale trickle-bed flow reactor with customized components on a commercially available system along with catalyst characterization and continuous temperature mapping. The optimized process achieved complete conversion with 3.8% catalyst loading (24% reduction versus batch processing) and maintained a robust performance over extended operations. This comprehensive development establishes a scalable, safer alternative to batch hydrogenation while reducing precious-metal usage, providing a template for pharmaceutical flow chemistry applications requiring heterogeneous catalysis.

  • Synthesis of N -Linked Amino-Hexyl Fluorotryptophan for Enlicitide, Part 2: Process Improvements toward Commercial Manufacture

    by Kai-Jiong Xiao, Yingju Xu, Alexandra C. Sun, Eric Sirota, Byron K. Peters, Jeffrey T. Kuethe, Timothy J. Wright, Ralph Zhao, Gurpreet Longia, Erica L. Schwalm, et al.

    Herein, we report the development of a robust manufacturing process for N-linked amino-hexyl fluorotryptophan 3, a key building block for enlicitide decanoate (MK-0616), which is an orally bioavailable inhibitor of proprotein convertase subtilisin/kexin type 9 (PCSK9). Targeted process development enabled safe operation of the Delépine reaction, increased yields for the hexamine hydrolysis and enzymatic tryptophan synthesis, and established a robust and selective N-alkylation of 5-fluorotryptophan. Collectively, these improvements afforded the target product with high yield, >98.5% purity, and favorable physical properties suitable for commercial manufacture.


  • Top Cited Papers

    Biocatalytic cascades enable manufacture of the macrocyclic peptide enlicitide

    by Artis Klapars, Anna Fryszkowska, Stephanie Galanie, Omer Ad, Ellen Y. Aguilera, Nnamdi Akporji, Chihui An, Stephanus Axnanda, Tewoderos M. Ayele, Richard S. Ayikpoe, et al.

    Historically, many compelling therapeutic targets have been accessible only by injectable biologic drugs. Macrocyclic peptides, such as the proprotein convertase subtilisin/kexin type 9 inhibitor enlicitide for the treatment of atherosclerotic cardiovascular disease, are beginning to unlock these targets to orally administered therapies to enable broader patient access. We report the convergent biocatalytic assembly of enlicitide from simple building blocks enabled by a suite of engineered enzymes to catalyze selective peptide fragment formation, coupling, and macrocyclization in a protecting group–free manner. Together with efficient crystallizations that obviate the need for chromatography, this approach reduces the number of steps by greater than half compared with prior state-of-the-art methods, addressing long-standing synthetic challenges and offering a sustainable blueprint for the scalable development of complex peptide therapeutics.


  • Open Access

    In Vitro and In Vivo Development of a β-Lactam-Metallo-β-Lactamase Inhibitor: Targeting Carbapenem-Resistant Enterobacterales

    by Byron K. Peters, Nakita Reddy, Mbongeni Shungube, Letisha Girdhari, Sooraj Baijnath, Sipho Mdanda, Lloyd Chetty, Thandokuhle Ntombela, Thilona Arumugam, Linda A. Bester, et al.

    β-lactams are the most prescribed class of antibiotics due to their potent, broad-spectrum antimicrobial activities. However, alarming rates of antimicrobial resistance now threaten the clinical relevance of these drugs, especially for the carbapenem-resistant Enterobacterales expressing metallo-β-lactamases (MBLs). Antimicrobial agents that specifically target these enzymes to restore the efficacy of last resort β-lactam drugs, that is, carbapenems, are therefore desperately needed. Herein, we present a cyclic zinc chelator covalently attached to a β-lactam scaffold (cephalosporin), that is, BP1. Observations from in vitro assays (with seven MBL expressing bacteria from different geographies) have indicated that BP1 restored the efficacy of meropenem to ≤ 0.5 mg/L, with sterilizing activity occurring from 8 h postinoculation. Furthermore, BP1 was nontoxic against human hepatocarcinoma cells (IC50 > 1000 mg/L) and exhibited a potency of (Kiapp) 24.8 and 97.4 μM against Verona integron-encoded MBL (VIM-2) and New Delhi metallo β-lactamase (NDM-1), respectively. There was no inhibition observed from BP1 with the human zinc-containing enzyme glyoxylase II up to 500 μM. Preliminary molecular docking of BP1 with NDM-1 and VIM-2 sheds light on BP1's mode of action. In Klebsiella pneumoniae NDM infected mice, BP1 coadministered with meropenem was efficacious in reducing the bacterial load by >3 log10 units' postinfection. The findings herein propose a favorable therapeutic combination strategy that restores the activity of the carbapenem antibiotic class and complements the few MBL inhibitors under development, with the ultimate goal of curbing antimicrobial resistance.


  • Electroreductive Olefin–Ketone Coupling

    by Pengfei Hu, Byron K. Peters, Christian A. Malapit, Julien C. Vantourout, Pan Wang, Jinjun Li, Lucas Mele, Pierre-Georges Echeverria, Shelley D. Minteer, Phil S. Baran

    A user-friendly approach is presented to sidestep the venerable Grignard addition to unactivated ketones to access tertiary alcohols by reversing the polarity of the disconnection. In this work a ketone instead acts as a nucleophile when adding to simple unactivated olefins to accomplish the same overall transformation. The scope of this coupling is broad as enabled using an electrochemical approach, and the reaction is scalable, chemoselective, and requires no precaution to exclude air or water. Multiple applications demonstrate the simplifying nature of the reaction on multistep synthesis, and mechanistic studies point to an intuitive mechanism reminiscent of other chemical reductants such as SmI2 (which cannot accomplish the same reaction).


  • Electrochemical C(sp3)–H Fluorination

    by Yusuke Takahira, Miao Chen, Yu Kawamata, Pavel Mykhailiuk, Hugh Nakamura, Byron K. Peters, Solomon H. Reisberg, Chao Li, Longrui Chen, Tamaki Hoshikawa, et al.

    A simple and robust method for electrochemical alkyl C–H fluorination is presented. Using a simple nitrate additive, a widely available fluorine source (Selectfluor), and carbon-based electrodes, a wide variety of activated and unactivated C–H bonds are converted into their C–F congeners. The scalability of the reaction is also demonstrated with a 100 gram preparation of fluorovaline.


  • Top Cited Papers

    Scalable and safe synthetic organic electroreduction inspired by Li-ion battery chemistry

    by Byron K. Peters, Kevin X. Rodriguez, Solomon H. Reisberg, Sebastian B. Beil, David P. Hickey, Yu Kawamata, Michael Collins, Jeremy Starr, Longrui Chen, Sagar Udyavara, et al.

    Scaled-up sodium-free Birch reductions: The so-called Birch reduction is frequently used by chemists despite its daunting conditions: Pyrophoric sodium is dissolved in pure liquified ammonia to achieve partial reduction of aromatics. Peters et al. surveyed and then optimized small-scale electrochemical alternatives to devise a safer protocol that can work on a larger scale with a broad range of functionally complex substrates. Science , this issue p. 838


  • Open Access

    An unexpected re-arrangement of the antibiotic carbapenem core to new 1,4-diazepin-5-one scaffolds

    by Byron K. Peters, Rufaro Razuwika, Marivel Samipillai, Per I. Arvidsson, Hendrik G. Kruger, Thavendran Govender, Tricia Naicker

    Herein we report a peculiar organocatalyzed domino-reaction on the carbapenem core structure. As previously reported, 30 mol% of proline yields diazabicyclo[4.2.1]nonane analogues, while we currently report the formation of novel 1,4-diazepin-5-ones from the same starting material in the presence of 100 mol% proline. The inherent chirality of the starting material led to the stereochemical preference of the products with excellent diastereoselectivity (>99 : 1). The diazepinone products were confirmed using X-ray diffraction and 2D-NMR structure elucidation. A plausible mechanism of the re-arrangement, involving an unactivated retro-Dieckmann condensation, is also presented.


  • Enantio- and Regioselective Ir-Catalyzed Hydrogenation of Di- and Trisubstituted Cycloalkenes

    by Byron K. Peters, Jianguo Liu, Cristiana Margarita, Wangchuk Rabten, Sutthichat Kerdphon, Alexander Orebom, Thomas Morsch, Pher G. Andersson

    A number of cyclic olefins were prepared and evaluated for the asymmetric hydrogenation reaction using novel N,P-ligated iridium imidazole-based catalysts (Crabtree type). The diversity of these cyclic olefins spanned those having little functionality to others bearing strongly coordinating substituents and heterocycles. Excellent enantioselectivities were observed both for substrates having little functionality (up to >99% ee) and for substrates possessing functional groups several carbons away from the olefin. Substrates having functionalities such as carboxyl groups, alcohols, or heterocycles in the vicinity of the C═C bond were hydrogenated in high enantiomeric excess (up to >99% ee). The hydrogenation was also found to be regioselective, and by controlling the reaction conditions, selective hydrogenation of one of two trisubstituted olefins can be achieved. Furthermore, trisubstituted olefins can be selectively hydrogenated in the presence of tetrasubstituted olefins.


  • Formal Total Synthesis of Aliskiren

    by Byron K. Peters, Jianguo Liu, Cristiana Margarita, Pher G. Andersson

    The efficient and selective formal total synthesis of aliskiren is described. Aliskiren, a renin inhibitor drug, has received considerable attention, primarily because it is the first of the renin inhibitor drugs to be approved by the FDA. Herein, the formal synthesis of aliskiren by iridium‐catalyzed asymmetric hydrogenation of two allylic alcohol fragments is reported. Screening a number of N,P‐ligated iridium catalysts yielded two catalysts that gave the highest enantioselectivity in the hydrogenation, which gave the saturated alcohols in 97 and 93 %ee. In only four steps after hydrogenation, the fragments were combined by using the Julia–Kocienski reaction to produce late‐stage intermediate in an overall yield of 18 %.